MedBioSphere
Articles Videos The Web  
    

Results of Phase 1 Clinical Trial

Selected Abstract

Results of Phase 1 Clinical Trial Show Excellent Safety Profile for IDDS.
Iontophoretic Drug Delivery System, Dermal Patch and a Direct Current Power Source With Lidocaine and Epinephrine (IDDS) SEATTLE, Oct. 24 /PRNewswire/ -- Dharma Therapeutics, Inc., ( Dharma ) Seattle, WA, a transdermal drug delivery company and wholly owned subsidiary of Transcutaneous Technologies ...
October 24, 2006; PR Newswire

Read the full article with a free-trial membership at HighBeam Research



Related Articles

1. Human Genome Sciences Reports Results of Phase 1 Clinical Trial of ABthrax(TM) for Use in Prevention and Treatment of Anthrax Infection; - Results Demonstrate the Safety and Tolerability of ABthrax -.
2. Human Genome Sciences Publishes Results of Phase 1 Clinical Trial of ABthrax(TM) for Use in Prevention and Treatment of Anthrax Infection.
3. Results of Phase 1 Clinical Trial Demonstrate That LymphoStat-B(TM) Is Safe and Biologically Active in Patients with Systemic Lupus Erythematosus.
4. Cara Therapeutics Announces Results of Phase 1 Clinical Trial of Novel Analgesic; CR665 Safe and Pharmacologically Active.
5. Human Genome Sciences Reports Results of Phase 1 Clinical Trial of HGS-ETR1 in Patients With Advanced Solid Tumors; - Interim results of Phase 1 study of HGS-ETR2 also reported -.
6. Human Genome Sciences Reports Results of Phase 1 Clinical Trial of Lymphostat-B(TM) in Patients with Systemic Lupus Erythematosus; - Results Presented at the 67th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals -.
7. Human Genome Sciences Reports Positive Results of Phase 1 Clinical Trial of CCR5 mAb in Patients Infected with HIV-1.
8. Results of Phase 1 Clinical Trial Show Excellent Safety Profile for IDDS.
9. PowderMed's DNA-Based Flu Vaccine Shows Cross-Protective Immunity against Genetically-Drifted Flu Strains, Offering Potential for Vaccine Effective against Emerging Flu Variants.
10. PR Newswire Mid-Atlantic Summary, Monday, April 21 Through 3:00 P.M. ET.